Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017 at 3:00 p.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to share several features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 [email protected] Investors: Kimberly Minarovich +1 646 368 8014 [email protected]
